Skip to main content
. 2018 Mar 22;10(4):71–90. doi: 10.1177/1759720X18759291

Figure 1.

Figure 1.

Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flow diagram for systematic review of the fracture risks associated with breast cancer treatments.

aNo tamoxifen;

bNo AIs.

AIs, aromatase inhibitors; BMD, bone mineral density; RCT, randomized controlled trial; Tam, tamoxifen.